Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beyond the US submisson process.

Maria Donawa1

  • 1Donawa & Associates Ltd, Rome, Italy. donawa@srd.it

Medical Device Technology
|July 17, 2004
PubMed
Summary
This summary is machine-generated.

Companies must navigate all United States regulations, not just marketing authorization, to avoid product launch delays and Food and Drug Administration (FDA) enforcement actions. Comprehensive regulatory compliance is crucial for successful market entry.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

US regulation of combination products.

Medical device technology·2010
Same author

Clinical studies in Italy.

Medical device technology·2010
Same author

Meeting US and European supplier control requirements.

Medical device technology·2009
Same author

Avoiding surprises when implementing a single quality system.

Medical device technology·2009
Same author

Addressing Eeuropean environmental legislation.

Medical device technology·2009
Same author

Addressing US and European device testing requirements.

Medical device technology·2008

Area of Science:

  • Regulatory Affairs
  • Pharmaceuticals
  • Market Entry Strategy

Background:

  • Companies face significant challenges in complying with United States marketing authorization regulations.
  • Failure to adhere to all applicable US regulations can result in market entry delays.
  • Postmarketing enforcement actions by the Food and Drug Administration (FDA) pose a risk.

Purpose of the Study:

  • To identify common pitfalls in US regulatory compliance beyond initial marketing authorization.
  • To provide actionable strategies for companies to prevent regulatory non-compliance issues.
  • To enhance understanding of FDA postmarketing enforcement actions and their implications.

Main Methods:

  • Review of a case study involving a product launch in the US market.

Related Experiment Videos

  • Analysis of regulatory non-compliance leading to market delays and FDA actions.
  • Identification of key regulatory areas often overlooked by companies.

    • Main Results:

    • A company experienced significant delays and FDA enforcement due to non-compliance with regulations outside of initial marketing authorization.
    • The specific nature of the overlooked regulations and their impact are detailed.
    • The study highlights the critical need for a holistic approach to regulatory compliance.

    Conclusions:

    • Comprehensive regulatory due diligence is essential for a successful product launch in the US.
    • Companies must proactively identify and comply with all relevant US federal and state regulations.
    • Implementing robust internal compliance programs can mitigate risks of delays and FDA enforcement.